Functional characterization of T cells differentiated in vitro from bone marrow-derived CD34+ cells of psoriatic patients with family history

Experimental Dermatology

Volumn 19, Issue 8, 2010, Pages

  Zhang, Kaiming ^a   Li, Xinhua ^a   Yin, Guohua ^a   Liu, Yufeng ^b   Tang, Xuyuan ^a  

^a SHANXI MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Bone marrow; Haematopoietic cells; Psoriasis; T cells

Indexed keywords

CD3 ANTIGEN; CD34 ANTIGEN; T6 ANTIGEN;

ADULT; ARTICLE; BONE MARROW; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; KERATINOCYTE; MALE; MICROENVIRONMENT; PSORIASIS; T LYMPHOCYTE; TH1 CELL;

ADULT; ANTIGENS, CD34; BCL-X PROTEIN; BONE MARROW; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; CELL PROLIFERATION; COCULTURE TECHNIQUES; FAMILY HEALTH; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-8; KERATINOCYTES; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-MYC; PSORIASIS; STROMAL CELLS; T-LYMPHOCYTES;

EID: 77954838963     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2009.01016.x     Document Type: Article

References (39)

1. Nickoloff B J. The immunologic and genetic basis of psoriasis. Arch Dermatol 2000, 135:1104-1110.
2. Sabat R, Philipp S, Hoflich C. Immunopathogenesis of psoriasis. Exp Dermatol 2007, 16:779-798.
3. van Lingen R G, van de Kerkhof P C, de Jong E M. Reduced CD26bright expression of peripheral blood CD8+ T-cell subsets in psoriatic patients. Exp Dermatol 2008, 17:343-348.
4. Berth-Jones J. The use of ciclosporin in psoriasis. J Dermatolog Treat 2005, 16:258-277.
5. Krueger J G, Wolfe J T, Nabeya R T. Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. J Exp Med 1995, 182:2057-2068.
6. Gottlieb S L, Gilleaudeau P, Johnson R. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995, 1:442-447.
7. Abrams J R, Kelley S L, Hayes E. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000, 192:681-694.
8. Gordon K B, Papp K A, Hamilton T K. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003, 290:3073-3080.
9. Prinz J C, Gross B, Vollmer S. T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro via secreted products. Eur J Immunol 1994, 4:593-598.
10. Vollmer S, Menssen A, Trommler P. T lymphocytes derived from skin lesions of patients with psoriasis vulgaris express a novel cytokine pattern that is distinct from that of T helper type 1 and T helper type 2 cells. Eur J Immunol 1994, 24:2377-2382.
11. Bata-Csorgo Z, Hammerberg C, Voorhees J J. Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal stem keratinocytes. J Clin Invest 1995, 95:317-327.
12. Nickoloff B J, Wrone-Smith T, Bonish B. Response of murine and normal human skin to injection of allogeneic blood-derived psoriatic immunocytes. Arch Dermatol 1999, 135:546-552.
13. Schon M P, Detmar M, Parker C M. Murine psoriasis-like disorder induced by naive CD4 + T cells. Nat Med 1997, 3:183-188.
14. Nickoloff B J, Wrone-Smith T. Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis. Am J Pathol 1999, 155:145-158.
15. Boyman O, Hefti H P, Conrad C. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med 2004, 199:731-736.
16. Bowcock A M, Cookson W O. The genetics of psoriasis, psoriatic arthritis and atopic dermatitis. Hum Mol Genet 2004, 13:R43-R55.
17. Nickoloff B J, Nestle F O. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004, 113:1664-1675.
18. Nickoloff B J, Schroder J M, von den Driesch P. Is psoriasis a T-cell disease? Exp Dermatol 2000, 9:359-375.
19. Rosenzweig M, Marks D F, Zhu H. In vitro T lymphopoiesis of human and rhesus CD34+ progenitor cells. Blood 1996, 87:4040-4048.
20. Saito Y, Kametani Y, Hozumi K. The in vivo development of human T cells from CD34+ cells in the murine thymic environment. Int Immunol 2002, 14:1113-1124.
21. Brown D W, Baker B S, Ovigne J M. Skin CD4+ T cells produce interferon-gamma in vitro in response to streptococcal antigens in chronic plaque psoriasis. J Invest Dermatol 2000, 114:576-580.
22. Li X, Fan X, Zhang K. Influence of psoriatic peripheral blood CD4+ T and CD8+ T lymphocytes on C-myc, Bcl-xL and Ki67 gene expression in keratinocytes. Eur J Dermatol 2007, 17:392-396.
23. Eriksen K W, Lovato P, Skov L. Increased sensitivity to interferon-alpha in psoriatic T cells. J Invest Dermatol 2005, 125:936-944.
24. Szabo S K, Hammerberg C, Yoshida Y. Identification and quantitation of interferon-γ producing T cells in psoriatic lesions: localization to both CD4+ and CD8+ subsets. J Invest Dermatol 1998, 111:1072-1078.
25. Wrone-Smith T, Nickoloff B J. Dermal infection of immunocytes induces psoriasis. J Clin Invest 1996, 98:1878-1887.
26. Tomfohrde J, Silverman A, Barnes R. Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science 1994, 264:1141-1145.
27. Hüffmeier U, Steffens M, Burkhardt H. Evidence for susceptibility determinant(s) to psoriasis vulgaris in or near PTPN22 in German patients. J Med Genet 2006, 43:517-522.
28. Bowcock A M. The genetics of psoriasis and autoimmunity. Annu Rev Genomics Hum Genet 2005, 6:93-122.
29. Lacaud G, Gore L, Kennedy M. Runx1 is essential for hematopoietic commitment at the hemangioblast stage of development in vitro. Blood 2002, 100:458-466.
30. Helms C, Cao L, Krueger J G. A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat Genet 2003, 35:349-356.
31. Kanamori H, Tanaka M, Kawaguchi H. Resolution of psoriasis following allogeneic bone marrow transplantation for chronic myelogenous leukemia: case report and review of the literature. Am J Hematol 2002, 71:41-44.
32. Woods A C, Mant M J. Amelioration of severe psoriasis with psoriatic arthritis for 20 years after allogeneic haematopoietic stem cell transplantation. Ann Rheum Dis 2006, 65:697.
33. Snowden J A, Heaton D C. Development of psoriasis after syngeneic bone marrow transplant from psoriatic donor: further evidence for adoptive autoimmunity. Br J Dermatol 1997, 137:130-132.
34. Zhang K, Zhang R, Li X. The mRNA expression and promoter methylation status of the p16 gene in colony-forming cells with high proliferative potential in patients with psoriasis. Clin Exp Dermatol 2007, 32:1365-2230.
35. Res P, Blom B, Hori T. Downregulation of CD1 marks acquisition of functional maturation of human thymocytes and defines a control point in late stage of human T cell development. J Exp Med 1997, 185:141-152.
36. Krueger J G. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002, 46:1-23.
37. Osterland C K, Wilkinson R D, St Louis E A. Expression of c-myc protein in skin and synovium in psoriasis and psoriatic arthritis. Clin Exp Rheumatol 1990, 8:145-150.
38. Wrone-Smith T, Johnson T, Nelson B. Discordant expression of bcl-xL and bcl-2 by keratinocytes in vitro and psoriatic keratinocytes in vivo. Am J Patho 1995, 146:1079-1088.
39. Boise L H, González-García M, Postema C E. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993, 74:597-608.